617 related articles for article (PubMed ID: 30524901)
1. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG; Lévesque S; Workenhe ST; Gujar S; Le Boeuf F; Clements DR; Fahrner JE; Fend L; Bell JC; Mossman KL; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2018; 7(12):e1503032. PubMed ID: 30524901
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S; Fukuhara H; Todo T
Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
[TBL] [Abstract][Full Text] [Related]
4. Trial Watch-Oncolytic viruses and cancer therapy.
Pol J; Buqué A; Aranda F; Bloy N; Cremer I; Eggermont A; Erbs P; Fucikova J; Galon J; Limacher JM; Preville X; Sautès-Fridman C; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Feb; 5(2):e1117740. PubMed ID: 27057469
[TBL] [Abstract][Full Text] [Related]
5. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
7. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
[TBL] [Abstract][Full Text] [Related]
8. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
10. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.
Lee NH; Kim M; Oh SY; Kim SG; Kwon HC; Hwang TH
Oncotarget; 2017 Jan; 8(1):1213-1225. PubMed ID: 27901484
[TBL] [Abstract][Full Text] [Related]
13. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
15. Current status of clinical trials assessing oncolytic virus therapy for urological cancers.
Taguchi S; Fukuhara H; Homma Y; Todo T
Int J Urol; 2017 May; 24(5):342-351. PubMed ID: 28326624
[TBL] [Abstract][Full Text] [Related]
16. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
[TBL] [Abstract][Full Text] [Related]
18. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.
Zhang Y; Liu Z
Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
